Literature DB >> 29199605

Modeling Mesenchymal Stem Cells in TMJ Rheumatoid Arthritis and Osteoarthritis Therapy.

Nedime Serakinci1, Gokce Savtekin2.   

Abstract

Stem cells have self-renewal capacity and an ability to differentiate into particular cell types generating mature cells. Mesenchymal stem cells (MSCs) have a significant role in tissue homeostasis, which leads into tissue regeneration. MSCs are rare pluripotent cells supporting hematopoietic and mesenchymal cell lineages. MSCs are also believed to have therapeutic power over temporomandibular joint (TMJ) disorders (TMDs). The most common type of TMD is articular disc displacement, which induces progressive degenerative changes. These changes lead to rheumatoid arthritis or osteoarthritis. In this review, use of human mesenchymal cells (hMSCs) for therapeutic treatment of inflammatory diseases of TMJ is discussed.

Entities:  

Mesh:

Year:  2017        PMID: 29199605     DOI: 10.1615/CritRevEukaryotGeneExpr.2017019380

Source DB:  PubMed          Journal:  Crit Rev Eukaryot Gene Expr        ISSN: 1045-4403            Impact factor:   1.807


  3 in total

Review 1.  Regeneration of temporomandibular joint using in vitro human stem cells: A review.

Authors:  Shan Gong; Chitra Priya Emperumal; Kamal Al-Eryani; Reyes Enciso
Journal:  J Tissue Eng Regen Med       Date:  2022-03-31       Impact factor: 4.323

Review 2.  Autologous Stem Cells Transplants in the Treatment of Temporomandibular Joints Disorders: A Systematic Review and Meta-Analysis of Clinical Trials.

Authors:  Maciej Chęciński; Kamila Chęcińska; Natalia Turosz; Monika Kamińska; Zuzanna Nowak; Maciej Sikora; Dariusz Chlubek
Journal:  Cells       Date:  2022-08-30       Impact factor: 7.666

3.  Transplantation of human ESC-derived mesenchymal stem cell spheroids ameliorates spontaneous osteoarthritis in rhesus macaques.

Authors:  Bin Jiang; Xufeng Fu; Li Yan; Shanshan Li; Dongliang Zhao; Xiaoyan Wang; Yanchao Duan; Yaping Yan; Enqin Li; Kunhua Wu; Briauna Marie Inglis; Weizhi Ji; Ren-He Xu; Wei Si
Journal:  Theranostics       Date:  2019-08-21       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.